TERN-701 is an oral allosteric BCR-ABL tyrosine kinase inhibitor (TKI). Image Credit: crystal light / Shutterstock.
TERN-701 is an oral allosteric BCR-ABL tyrosine kinase inhibitor (TKI) and is one of the two therapies that Terns plans to focus its resources on this year. The treatment is being evaluated in a Phase I CARDINAL trial (NCT06163430) in participants with chronic phase CML who experienced treatment failure on at least one prior second-generation TKI. Interim data from the trial is expected in H2 2024.
CML therapies arTERN-601ed to generate $3.5bn in sales across eight maobesityrmaceutical markets (the US, France, Germany, Italy, Spain, UK, Japan, and Canada), as per a GlobalData report. The current market leaders in the field include Bristol Myers Squibb’s Sprycel (dasatinib) and Novartis’ Tasigna (nilotinib). Sprycel and Tasigna generated $1.4bn and $1.8bn in global sales in 2023, according to the companies’ financials. Pearl Bio and Merck partner for discovery of cancer therapies
Pearl BioiosciMerck files patent for enhancedcancertherapy using viral vectors and immunosuppressants GlobalData is the parent company of Pharmaceutical Technology.
Selecta BiosciencesTerns paused the development of its most advanced candidate, the oral thyroid hormone receptor-beta (THR-β) agonist, TERN-501, as a treatment for nonalcoholic steatohepatitis (NASH), despite reporting positive data from the Phase IIa DUET trial (NCT05415722). The company cited the current regulatory and developmental MASH landscape for limiting funding for the NASH therapy. Meanwhile, Terns said it plans to evaluate TERN-501, as a combination therapy for obesity.
The company also has additional earlPharmaceutical Technology pipeline for obesity. TERN-800, an oral small molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulator, is currently in the discovery stage as an obesity treatment.